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A B S T R A C T
The human soluble Epoxide Hydrolase (hsEH) is an enzyme involved in the hydrolysis of endogenous anti-
inﬂammatory and cardio-protective signalling mediators known as epoxyeicosatrienoic acids (EETs). EETs’
conversion into the corresponding diols by hsEH generates non-bioactive molecules, thereby the enzyme in-
hibition would be expected to enhance the EETs bioavailability, and their beneﬁcial properties. Numerous in-
hibitors have been developed to target the enzyme, some of which are showing promising antihypertensive and
anti-inﬂammatory properties in vivo. Thus far, the preparation of the recombinant enzyme for enzymatic and
structural in vitro studies has been performed mainly using a baculovirus expression system. More recently, it
was reported that the enzyme could be exogenously expressed and isolated from E. coli, although limited
amounts of active protein were obtained. We herein describe two novel methods to yield pure recombinant
enzyme. The ﬁrst describes the expression and puriﬁcation of the full-length enzyme from eukaryotic cells
HEK293-F, whilst the second concerns the C-terminal domain of hsEH obtained from the cost-eﬀective and rapid
E. coli prokaryotic system. The two methods successfully generated satisfactory amounts of functional enzyme,
with virtually identical enzymatic activity. Overall, the protocols described in this paper can be employed for the
recombinant expression and puriﬁcation of active hsEH, to be used in future biomedical investigations and for
high-throughput screening of inhibitors for potential use in the treatment of cardiovascular disease.
1. Introduction
The human soluble Epoxide Hydrolase (hsEH – EC 3.3.2.10) is
composed by two independently folded domains [1–3], an N-terminal
domain (NTD) with phosphatase activity [3,4], and a C-terminal do-
main (CTD) which performs the hydrolysis of epoxy-fatty acids [3,5–7].
The CTD activity is involved in the homeostatic regulation of the car-
diovascular tone, mainly through the hydrolysis of the epoxyeicosa-
trienoic acids (EETs), endothelial-derived hyperpolarising factors able
to induce the relaxation of the vasculature in organs such as heart,
kidneys, and many others [8–10]. The products of the EETs hsEH-
mediated hydration, namely dihydroxyeicosatrienoic acids (DHETs),
have a considerably reduced biological activity [10]. In the last 30
years, great eﬀorts have been directed towards designing and synthe-
sising eﬀective inhibitors of hsEH CTD activity, with the ultimate aim to
enhance the EETs’ bioavailability. This led to the discovery of several
compounds able to reduce the enzyme hydrolytic activity in vitro with
high potency and with promising in vivo eﬃcacy in animal models of
hypertension, atherosclerosis, diabetes, inﬂammation, pain, pulmonary
disease and immunological disorders [11,12]. Of the thousands of
compounds developed thus far, only few reached clinical trials. The two
sEH inhibitor AR9281 [13] and AUDA [14] failed in a phase IIa study
due to lack of eﬃcacy [15,16]. Two phase I clinical trials with the
GlaxoSmithKline compound GSK2256294 [17] have been recently
completed. The results are still pending, even though no positive out-
comes have been revealed yet [18,19]. As none of the thus far
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established antagonists exhibited absorption, distribution, and phar-
macokinetics properties suitable for advanced clinical trials, the search
for novel drug candidates is still an active ﬁeld [12]. The rapid and cost-
eﬀective development of new compounds depends on the easy and
manageable protocols of preparation of the hsEH. The great majority of
the drug discovery studies on hsEH have been carried out producing the
enzyme from S. frugiperda insect cells, via baculovirus recombinant
expression [20–22]. However, this method is time-consuming and la-
borious. More recently, Nishi et al. [23] reported a protocol for the
recombinant expression of the full-length human enzyme in E. coli. The
puriﬁed enzyme showed virtually identical speciﬁc activity and in-
hibition properties of the recombinant enzyme prepared from insect
cells. However, the yield of puriﬁed hsEH full-length (hsEH FL) ob-
tained from prokaryotic cells was reported to be rather low (around
2mg/L). Herein, we present a novel protocol of expression and pur-
iﬁcation of the recombinant hsEH FL, that yields milligrams of pure and
active recombinant enzyme. This alternative method utilises the
mammalian cells FreeStyle™ HEK293 (HEK293-F) [24]. Beyond the FL
protein, Tanaka et al. [25] reported recently the ﬁrst structure of the
hsEH CTD, in complex with two novel inhibitors of the epoxy-hydro-
lytic activity of the enzyme, indicating that the CTD in isolation could
be utilised to screen new libraries of hsEH antagonists. Although the
CTD was obtained by recombinant expression in E. coli, very little detail
on the protein expression and puriﬁcation system was provided in the
previous report. In this paper, we describe a thorough protocol of
prokaryotic expression of the isolated CTD, along with an optimised
puriﬁcation method to yield milligram amounts per litre of pure protein
for biological investigations and drug discovery studies.
In addition to protein cloning, expression, and puriﬁcation of the
hsEH FL and CTD, the enzymatic speciﬁc activity of the recombinant
enzymes was also compared and will be herein described.
2. Materials and methods
2.1. Cloning of hsEH FL in mammalian expression vector
The cDNA of hsEH FL was kindly provided by Dr C Morisseau (UC
Davis) and was cloned into the pcDNA3.1D/V5-His-TOPO® vector
(Invitrogen) using the pcDNA3.1 Directional TOPO® Expression Kit
(Invitrogen). The hsEH FL cDNA was PCR-ampliﬁed using primers de-
signed to facilitate directional cloning (Table 1), as detailed in the kit
instructions, generating a blunt-end PCR product that was mixed using
a molar ratio of 1:1 of insert:TOPO® vector. The mixture was then used
to chemically transform One shot® TOP10 E. Coli competent cells.
Successful cloning was conﬁrmed by sequencing (MWG Euroﬁns). The
mammalian expression vector cloned with the hsEH FL cDNA was ﬁ-
nally ampliﬁed in E. coli DH5α C2987 competent cells (NEB) and
puriﬁed using the Pure Yield™ Plasmid Maxiprep system (Promega), out
of a 0.5 L bacterial culture.
2.2. Expression of hsEH FL in HEK293-F cells
A vial containing 1×107 viable FreeStyle™ 293-F cells (HEK293-F –
ThermoFisher Scientiﬁc) was transferred into a disposable Erlenmeyer
ﬂask (Sigma) previously ﬁlled with 30mL of pre-warmed FreeStyle 293
Expression Serum-Free Medium™ (SFM – ThermoFisher Scientiﬁc). The
cells were cultured for two days at 37 °C, 8% CO2, and 100 rpm, in a
shacking incubator, up to a density of 1–3× 106 cells/mL and 90%
viability. Cells were sub-cultured four times, every two days of in-
cubation, in 30mL of fresh SFM to 0.2–0.5×106 cells/mL. During the
ﬁfth and last passage, the cells were seeded in 125mL of fresh medium
to 1× 106 cells/mL. After 48 h, the cells were prepared for transfection,
being resuspended at a cell density of 2×106 cells/mL in 250mL of
fresh pre-warmed SFM. The vector and the transfection agent poly-
ethylenimine (Sigma) were added to the cells to a ﬁnal concentration of
respectively 3 μg/mL and 9 μg/mL. After 24 h, the culture was diluted
1:1 in pre-warmed SFM supplemented with 2.2 mM Valproic Acid
(Sigma). Three days later the cells were collected by centrifugation at
1200 rpm for 20min at room temperature and stored at −20 °C.
2.3. Cloning of hsEH CTD in bacterial expression vector
A modiﬁed pET3a plasmid, containing a hexahistidine tag (His-tag)
and a TEV (tobacco etch virus) cleavage site (MHHHHHHSTENLYFQ-
GSS) in the multiple cloning site, was provided by the Protein
Production Facility of King's College London. The cDNA of the hsEH
CTD (amino acids 230–555) was cloned in the plasmid using the IN-
Fusion® cloning ligation-independent system (Clontech Laboratories
Inc.) [26]. The cDNA was PCR-ampliﬁed with the DNA polymerase
KOD Hot Start Master Mix (EMD Millipore), using “chimeric” primers
designed with the IN-fusion® primer design web tool, characterised by a
sequence that overlaps with the gene of interest, and a region com-
plementary to the vector (Table 2). The template used was the mam-
malian expression vector containing the hsEH FL, described above. The
plasmid pET3a was double digested for 3 h at 37 °C with BamHI/PstI
(NEB), and the restriction enzymes were inactivated for 20min at 80 °C.
Plasmid and insert were mixed with a molar ratio of 1:3 respectively,
and incubated with the In-Fusion HD Enzyme Premix for 30min at
50 °C. The DNA was then used to transform DH5α C2987 E. coli com-
petent cells. Successful cloning was conﬁrmed by sequencing (Source
Bioscience).
2.4. Expression of hsEH CTD in E. Coli
The pET3a containing hsEH CTD cDNA was transformed in chemi-
cally competent Ros2™(DE3) (EMD Millipore). A single colony of
transformed cells was inoculated in 50mL of ZYP5052 auto-induction
medium [27] and cultured at 30 °C and 200 rpm overnight. The culture
was diluted 1:100 in 3× 1 L Erlenmeyer ﬂasks ﬁlled up with fresh
ZYP5052 medium and cultured at 37 °C and 200 rpm until the optical
density of 0.5 was reached. The incubation temperature was then
lowered to 18 °C and cells cultured for 24 h at 200 rpm. At the end of
the incubation, the cells where centrifuged at 5000× g for 30min at
4 °C and the pellets stored at −20 °C.
2.5. Ni2+-IMAC chromatography
The pellets obtained from mammalian cells growths were re-
suspended in 5mL/g of wet cells of lysis buﬀer (50mM Tris-HCl pH 8,
300mM NaCl, 10 mM imidazole, 5% glycerol, 2 mM PMSF, 2mM
MgCl2, 0.2mM EDTA, 15 μg/mL benzamidine, a tablet of cOmplete™
protease inhibitor cocktail (Roche) per 50mL of buﬀer), and the cells
broken with three thaw-and-freeze cycles in liquid nitrogen. Pellets
from bacterial cultures were resuspended in 2mL/g of wet cells of lysis
buﬀer (same as before, added with 0.01 g of lysozyme), to be sonicated
on ice with a Vibra-Cell™ sonicator (Sonics) for 10min (3 s pulse ON
and 10 s pulse OFF). Both mammalian and bacterial lysates were then
centrifuged at 38800×g for 1 h at 4 °C, and the supernatants passed
through a 0.45 μm ﬁlter (Millipore). The soluble fractions were loaded
onto a 5mL HisTrap™ FF Nickel Sepharose Column (GE Healthcare),
Table 1
Primers used in the cloning of the hsEH FL into pcDNA™3.1D/V5-His-TOPO®
vector. The primers were synthesised by Sigma.
Primer Sequence
Forward 5′ CACCATGACGCTGCGCGCGGCC 3′
Bold: pcDNA™3.1D/V5-His TOPO® annealing sequence to enable
directional cloning
Underlined: ATG initiation codon
Normal: hsEH FL cDNA annealing sequence
Reverse 5′ CATCTTTGAGACCACCGGTGG 3′
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previously equilibrated with binding buﬀer (50mM Tris-HCl pH 8,
300mM NaCl, 10mM imidazole, 5% glycerol). The bound species were
eluted in 1.5mL fractions, applying a 0–60% gradient in 30 column
volumes (CVs) of elution buﬀer (50mM Tris-HCl pH 8, 300mM NaCl,
300mM imidazole, 5% glycerol). The fractions containing hsEH were
pooled and dialysed at 4 °C overnight, in 20mM MOPS pH 7.4, 75mM
NaCl, 1 mM EDTA, 2mM DTT.
2.6. Benzylthio-Sepharose (BTS) chromatography
The Benzylthio-Sepharose (BTS) is an improved aﬃnity chromato-
graphy resin for the puriﬁcation of Epoxide Hydrolases. The resin was
synthesised in-house using a protocol adapted from Winxtrom et al.
[28]. 10mL of CL-6B® Sepharose resin (Sigma Aldrich) were poured
onto a 15mL polypropylene gravity column (Pierce), and washed with
10 CVs of water, 10 CVs of 50% MeOH, and 10 CVs of 0.1 M NaOH. The
resin was then transferred in a 100mL frosted neck round-bottom ﬂask,
containing 20mL of 0.3 M NaOH, and 2mL of 1,4-butanediol diglycidyl
ether (activation solution), then cooled down for 30min on ice while
shaking. 60 mg of NaBH4 were added, and the epoxy-activation of the
Sepharose was carried out at room temperature for 5 h on an orbital
shaker in a fume hood (note that the ﬂask was sealed with an aerated
rubber stopper, to allow the release of the H2 generated by the reac-
tion). The activated resin was transferred in a sintered-glass funnel and
washed with 20 CVs of water pH 6, 20 CVs of 50% MeOH, 20 CVs of
MeOH, 20 CVs of 50% MeOH, and 20 CVs of water pH 6. The resin was
resuspended in 20mL of activation solution, added with 50mL of
benzyl mercaptan, and left to swirl for 24 h at room temperature in a
fume hood. The derived resin was transferred on a sintered glass funnel,
and washed with 40 CVs of 50% MeOH, 40 CVs of MeOH, 40 CVs of
50% MeOH, 40 CVs of water, 40 CVs of 0.5 M NaCl, 40 CVs of water, 40
CVs of 0.001M HCl to hydrolyse the unreacted epoxy-groups, 40 CVs of
water, and 40 CVs of 50% EtOH. The resin was then split in aliquots of
2.5 mL in gravity columns and washed with 10 CVs of EtOH. The ﬁnal
BTS resin was stored at 4 °C in 0.1% of butylated hydroxyanisole.
Proteins subjected to dialysis after IMAC puriﬁcation were loaded
onto the BTS resin previously equilibrated with binding buﬀer (20mM
MOPS pH 7.4, 75mM NaCl, 1 mM EDTA, 2mM DTT, 5% glycerol).
After washing the column with 2.5 CVs of binding buﬀer, hsEH proteins
were eluted with 10 CVs of elution buﬀer (20mMMOPS pH 7.4, 75mM
NaCl, 1 mM EDTA, 2mM DTT, 5% glycerol, 1 mM 2-benzoyl-3-pheny-
loxirane). Purity and state of the protein were veriﬁed by SDS-PAGE,
and the fractions containing protein were dialysed at 4 °C overnight in
137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 3mM KH2PO4, pH 7.4,
0.2 mM EDTA, 1mM DTT.
2.7. Size-exclusion chromatography (SEC)
Protein samples were concentrated up to 5mL, ﬁltered with 0.2 μm
ﬁlters (Millipore) and loaded onto a HiLoad 16/600 Superdex 75pg SEC
(GE Healthcare), previously equilibrated with 137mM NaCl, 2.7mM
KCl, 10mM Na2HPO4, 3mM KH2PO4, pH 7.4, 0.2mM EDTA, 1mM
DTT, 5% glycerol. Fractions containing hsEH proteins were pooled to-
gether and dialysed overnight at 4 °C in 50mM TRIS-HCl pH 7.4,
300mM NaCl, 20% glycerol. After dialysis, samples were concentrated
to 1mg/mL (concentration adjusted according to the theoretical mo-
lecular weight and extinction coeﬃcient, obtained using the
ProtPARAM ExPASY tool [29]), ﬂash frozen in small aliquots using li-
quid nitrogen, and stored at −80 °C.
2.8. Western blots
For immunoblotting, the samples were initially run on SDS-PAGE
(using Laemmli protocol [30]) at 170 V for 60min, to be then trans-
ferred onto a PVDF membrane (Sigma) for 1 h at 100 V (cooled with ice
packs). The membranes were blocked with PBS and 10% milk, at room
temperature in agitation for 1 h. After three washes of 10min with 5mL
PBS-T (PBS, 0.1% Tween®-20), the membranes were exposed to the
primary antibody in PBS-T added with 2% milk (mouse anti-6×His-tag
1:5000 – Stratech CSB-MA000011M0m; rabbit anti-hsEH 1:1000 –
Stratech CSB-PA007735LA01HU), shaken for 1 h at room temperature.
After being washed three times for 10min with 5mL PBS-T, the
membranes were exposed to HRP-conjugated secondary antibody in
PBS-T added with 2% milk (goat-anti-mouse 1:5000 – Dako P0447;
goat-anti-rabbit 1:2000 – Dako P0448). After 1 h in agitation at room
temperature, the membranes were washed three times for 10min, two
times with 5mL PBS-T, and a last time with PBS. The detection was
carried out using the Enhanced Chemiluminescent Luminol (Promega).
2.9. Electrospray ionisation mass spectrometry (ESI-MS)
The intact protein MS experiments were performed using a maXis
(Bruker) calibrated using the tuning mix ES-TOF (ESI) positive
(Agilent). The proteins were dialysed overnight at 4 °C in 25mM HEPES
pH 7.4, 300mM NaCl, 10% glycerol, 1 mM DTT, to be then con-
centrated to 5–10mg/mL. The samples for ESI-MS were prepared di-
luting the proteins at a ﬁnal concentration of 60 μg/mL in 0.1% formic
acid, to be then loaded onto a Hamilton syringe and directly injected
into the spectrometer using a motorised pump with a ﬂow rate of
10–50 μL/min. The spectra were recorded for 3min and a spectral rate
of 1 Hz, with an end plate oﬀset of −500 V, a capillary voltage of
−4500 V, and a nebuliser pressure of 3.0 Bar. The detection of the
spectra was performed setting the funnel and multipole RF at 400 Vpp,
tuning the ISCID energy between 80 and 110 eV to optimise the signal-
to-noise ratio, and selecting an ion energy of 3 eV.
2.10. Speciﬁc activity measurements
The enzyme speciﬁc activity was evaluated using a rapid continuous
spectroﬂuorometric method developed by Wolf et al. [31]. The assay
utilises the synthetic substrate 3-phenyl-cyano(6-methoxy-2-naphtha-
lenyl) methyl ester-2-oxiraneacetic acid (PHOME – Cayman), which is
hydrolysed by Epoxide Hydrolases, generating a detectable ﬂuorescent
end-product called 6-methoxy-2-naphtaldehyde (6M2N). The
Table 2
Primers used in the IN-Fusion cloning of the hsEH CTD. The primers were synthesised by Sigma.
Primer Sequence
Forward 5′ ACCACAGCCAGGATCCAACCTCTTGCAATCCAAGTGA 3′
Bold: pET3a annealing sequence
Italic: BamHI restriction enzyme
Normal: hsEH CTD cDNA annealing sequence
Reverse 5′ GCAAGCTTGTCGACCTGCAGTCATTACATCTTTGAGACCACCGGTG 3′
Bold: pET3a annealing sequence
Italic: PstI restriction enzyme
Underlined: Stop Codons
Normal: hsEH CTD cDNA annealing sequence
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recombinant enzymes were thawed on ice and diluted with reaction
buﬀer (25mM TRIS-HCl pH 7.4) to 0.2, 0.4, 0.8, 1.6, 4, 8 μM con-
centrations, in previously cooled tubes. The aliquots were mixed with
10 μM TCEP for 15min on ice and diluted 1:40 v/v in reaction buﬀer in
a 96-well polystyrene microtiter plate (Thermo Scientiﬁc). A fresh
0.4 mM solution of PHOME was prepared in DMSO, to be then diluted
1:40 v/v in the 96-well plate. The measurements of the relative ﬂuor-
escence units (RFUs) were carried out for 20min using a POLARstar
Omega (BMG Labtech), with the following setup: excitation wavelength
330 nm, emission wavelength 460 nm, detection every 45 s, gain 750,
and 30 °C constant temperature. Measurements were performed in four
replicates, and each experiment was repeated three times. For quanti-
ﬁcation purposes, a conversion curve was built reporting the 6M2N
ﬂuorescence as function of the ﬂuorophore concentration. A series of
6M2N (Sigma) solutions with concentrations ranging between 0.01 and
10mM were prepared in DMSO and diluted 1:25 v/v into reaction
buﬀer. These solutions were then diluted 1:4 v/v into buﬀer in the 96-
well plate and an endpoint ﬂuorescence measurement was performed
(same setting as before). The correlation between the ﬂuorescence de-
tected and the nmol of 6M2N was calculated by linear regression, and
the slope used to convert the RFUs of the speciﬁc activity measurements
into moles of product. Upon determination of the speciﬁc activity, the
Turnover Frequency (TOF) was calculated. The hsEH FL and CTD TOFs
were compared with one-tailed homoscedastic t-test and reported in the
plots as average ± SEM. The statistical signiﬁcance was set up at
minimum p 0.05.
3. Results and discussion
3.1. Cloning of hsEH FL in TOPO pcDNA™3.1
Based on the cDNA sequence of the hsEH FL kindly provided by Dr C
Morisseau and the instructions of the pcDNA3.1 Directional TOPO®
Expression Kit, a set of primers were designed (Table 1) to PCR-amplify
the region corresponding to the hsEH FL cDNA. The ampliﬁcation was
conﬁrmed by electrophoresis. The TOPO cloning reaction was set up
mixing the blunt ended PCR product obtained and the pcDNA™3.1D/
V5-His TOPO® vector. After transformation of the One shot® TOP10 E.
Coli competent cells, conﬁrmation of successful cloning was attained by
sequencing of cDNA extracted from one of the colonies obtained
(Supplementary material A).
3.2. Cloning of hsEH CTD in pET3a
Based on the cDNA sequence of the hsEH FL, a set of “chimeric”
primers were designed (Table 2) to PCR-amplify the region corre-
sponding to hsEH CTD cDNA (amino acids 230–555). The ampliﬁcation
of the PCR product, as well as the successful double digestion of the
pET3a vector with BamHI/PstI were conﬁrmed by electrophoresis. The
IN-fusion reaction was set up and the mixture was transformed in
homemade competent DH5α C2987 E. coli cells. The successful cloning
was conﬁrmed by sequencing of cDNA (Supplementary material B),
extracted from one of the colonies obtained.
3.3. Optimisation of the expression conditions of hsEH CTD in E. Coli
Nishi et al. [23] previously reported a protocol of expression of hsEH
FL in E. coli BL21(DE3) using the auto-induction media ZYP5052, given
that induction with isopropyl-β-D-thiogalactopyranoside (IPTG) led to
recombinant protein accumulation in inclusion bodies. We tested whether
IPTG induction of Ros2™(DE3) cultured in Luria Broth or Terriﬁc Broth
produced insoluble hsEH CTD: in agreement with what was observed for
the full-length recombinant enzyme [23], the CTD was also yielded ex-
clusively in inclusion bodies at diﬀerent induction temperatures, IPTG
concentration and induction times (data not shown). However, using the
autoinduction ZYP5052 media, the amount of hsEH CTD present in the
soluble fraction increased noticeably. Transformed Ros2™(DE3) cells were
cultured at 37 °C, up to three diﬀerent levels of optical density (OD600nm)
(0.5, 1, and 1.5), then the temperature was lowered to 18 °C and the cells
cultured for either 16 or 24 h. Although most of the protein was still found
in the insoluble fractions, detectable levels of soluble protein were ob-
served when the cells were cultured at 37 °C up to an OD600 of 0.5, fol-
lowed by 24 h incubation at 18 °C (Fig. 1). These optimised expression
conditions were used for large-scale cultures. 2 L Erlenmeyer ﬂasks were
ﬁlled up with a volume of maximum 1 L of ZYP5052, to allow an ade-
quate aeration of the medium during the long growth. Expression tests of
the cultures were in agreement with the small-scale expression tests: most
of the protein was insoluble, but detectable levels of soluble hsEH CTD
were retained in solution.
3.4. Puriﬁcation of hsEH FL
Upon transfection of HEK293-F cells and expression of recombinant
hsEH FL, pellets of ∼5 g of dry cells were obtained by centrifugation
and stored at −20 °C. The cells were broken, and the lysate prepared
for the puriﬁcation. Taking advantage of the His-tag engineered at the
C-terminus of the protein, the ﬁrst stage of the hsEH FL puriﬁcation was
a Nickel IMAC. Fig. 2A shows the elution proﬁle of the cell lysate
through the HisTrap™ FF Nickel Sepharose Column. The SDS-PAGE
analysis of the eluted fractions revealed the presence of hsEH FL in the
peak eluted at approximately 22% of elution buﬀer, corresponding to
about 70mM imidazole (Fig. 2B). The fractions containing the protein
of interest were dialysed overnight and loaded onto the BTS column, an
aﬃnity resin able to bind hsEH through the interaction of its CTD and
the benzyl mercaptan moieties immobilised on Sepharose units [28].
SDS-PAGE analysis showed an improvement in the purity of hsEH FL
(Fig. 2C) following this second puriﬁcation step. As a ﬁnal puriﬁcation
step, SEC was performed with the aim of removing any residual con-
taminant and preparing the protein for biochemical analysis. The SEC
chromatogram, shown in Fig. 2D, indicated that the protein eluted in
two peaks. The ﬁrst peak showed an elution volume above the void
volume of the column used, suggesting that part of the protein ag-
gregated. The second peak exhibited an approximate elution volume of
50mL, and the SDS PAGE analysis (Fig. 2E) revealed that it contained
the hsEH FL. The fractions corresponding to the former peak were
pooled together, yielding around 2mg of protein from only 250mL of
transfected HEK293-F cells.
Fig. 1. hsEH CTD expression tests in Ros2(DE3) E.
coli cultured in ZYP5052 auto-induction media.
hsEH CTD expressed well, with most of the protein
being retained in the insoluble fractions. The best
conditions for soluble proteins consisted in growing
the cells at 37 °C up to an OD600nm of 0.5, followed
by 24 h at 18 °C (eighth lane from left). MWM: mo-
lecular weight marker; B.S.: before temperature
switch; T.C.: total cells; I.F.: insoluble fraction; S.F.:
soluble fraction; OD600nm: optical density at 600 nm.
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3.5. Puriﬁcation of hsEH CTD
After expression of hsEH CTD in Ros2™(DE3) cells, pellets of
10–15 g/L of cells were harvested. As per the full-length protein, the
ﬁrst step of puriﬁcation was a Ni2+-IMAC, taking advantage of the His-
tag engineered at the N-terminus of the construct. The elution proﬁle
showed two peaks (Fig. 3A), of which only the second contained hsEH
CTD (Fig. 3B). The protein was then subjected to BTS aﬃnity chro-
matography, obtaining a signiﬁcant improvement of the purity
(Fig. 3C). A ﬁnal SEC chromatography step was performed revealing
that hsEH CTD eluted in a single and sharp peak (Fig. 3E), indicative of
a monomeric and monodisperse protein. The ﬁnal sample showed high
purity by SDS PAGE analysis (Fig. 3E). Approximately 20mg of pure
protein were yielded from 3 L of bacterial culture.
3.6. Characterisation of hsEH CTD and FL
Electrospray ionisation mass spectrometry (ESI-MS) and Western
blotting conﬁrmed the identity of the puriﬁed proteins. The ESI-MS ex-
periments were performed spraying hsEH CTD and FL in positive ioni-
sation conditions, detecting the m/z intensity of the species in solution.
The spectra showed a Gaussian-type distribution of peaks ranging from
m/z 1275.2 to 2475.7 for the CTD, and 1196.3–2289.7m/z for the FL
(Fig. 4A and C). Through maximum entropy deconvolution, the plots
shown in Fig. 4B and D were generated. In the case of hsEH CTD, the mass
proﬁle was dominated by a species with a molecular weight of
39497.9 Da, virtually identical to the expected mass of 39498.2Da
computed in ProtParam. The mass proﬁle of hsEH FL was dominated by a
species with a molecular weight of 67582.1 Da, corresponding to the
expected mass of the recombinant protein upon N-terminal methionine
excision [32] (67711.25 Da–131.19 Da=67580.06 Da) (Fig. 4C). In ad-
dition to the main species, additional minor peaks at higher masses could
be detected, attributed to counter ions bound to hsEH FL.
Western blotting analyses were performed on puriﬁed hsEH CTD
and FL, stained with two diﬀerent primary antibodies: a mouse anti-
His-tag monoclonal antibody (taking advantage of the His-tag en-
gineered in the recombinant enzymes) (Fig. 5A and C) and a rabbit anti-
human bifunctional Epoxide Hydrolase 2 (Fig. 5B and D). With both
antibodies, it was detected only one band at the expected molecular
weight for both hsEH CTD and FL, conﬁrming the nature and the high
purity of the protein samples.
Western Blot and ESI-MS experiments conﬁrmed the identity of the
recombinant hsEH CTD and FL expressed and puriﬁed from E. coli and
HEK293-F cells respectively.
3.7. Speciﬁc activity measurements
The speciﬁc activity of hsEH CTD and FL was determined via a
spectroﬂuorometric assay, using the synthetic substrate PHOME [31].
Protein solutions with increasing concentrations of hsEH CTD and FL
were prepared and diluted in the reaction buﬀer in adequate micro-
plates. A saturating ﬁnal concentration of the substrate PHOME was
then added, and the ﬂuorescence signal was monitored for 20min.
Fig. 6A reports the raw data obtained for hsEH CTD and FL, showing the
Fig. 2. Puriﬁcation of hsEH FL. A. IMAC elution proﬁle. The elution produced two peaks, distinguishable between fractions 5 and 42. B. SDS-PAGE analysis of IMAC.
The second elution peak contained hsEH FL. C. SDS-PAGE analysis following BTS puriﬁcation. Following IMAC, the sample resulted almost pure (as shown in the
“Before BTS” lane). The BTS aﬃnity puriﬁcation removed the minor residual contaminants. D. SEC elution proﬁle. The elution produced two peaks, between
fractions 12 and 45. E. SDS-PAGE analysis of SEC fractions. The hsEH FL was eluted in the second SEC peak. MWM: molecular weight marker; FT: ﬂow-through; Wash
A: wash with binding buﬀer; Wash B: wash with elution buﬀer.
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expected ﬂuorescence signal increase as function of protein con-
centration.
For accurate analysis, only the linear window of ﬂuorescence in-
crements between 0 and 10min of detection was considered, corre-
sponding to substrate-saturating conditions. The RFUs of the linear
interval were transformed in nmol of 6M2N, using the conversion
coeﬃcient (Supplementary material C). The initial velocities of sub-
strate conversion were determined as slopes of the straight lines ob-
tained by linear regression (R2≥ 0.9) (Fig. 6B) and plotted versus the
corresponding nmol of enzyme. The speciﬁc activity was determined by
linear regression of the data points and further considered only when
R2≥ 0.9 (Fig. 6C). The experiments were repeated at least three times,
obtaining average speciﬁc activities of 67.64 ± 12.78 and
36.29 ± 4.63 pmol min−1·mg−1 for hsEH CTD and FL respectively.
From the speciﬁc activity values obtained, the average TOF was cal-
culated, to normalise by the number of available active sites, and
compared with a one-tailed homoscedastic t-test (Fig. 7). The hsEH CTD
and FL exhibited TOF of respectively 2.67 ± 0.51 and
2.46 ± 0.31 nmol min−1·nmolenz−1. The t-test did not reveal any sig-
niﬁcant diﬀerence of the average TOF of hsEH CTD and FL, as antici-
pated, as that the N-terminal Domain is not expected to be involved in
the epoxy-groups hydrolysis [9].
4. Conclusion
hsEH is considered a key regulator of the cardiovascular home-
ostasis, a role exerted through the hydrolysis of endothelial signalling
modulators termed epoxyeicosatrienoic acids (EETs) [8]. Accumulating
evidence indicate that hsEH inhibition may be a potential strategy to
increase the bioavailability of the EETs and enhance their beneﬁcial
cardioprotective activities. At the ﬁrst stages of the hsEH inhibitors
research, the enzyme used to be isolated from organs of diﬀerent animal
sources such as rats, mice, monkeys, and humans, through tissue
homogenisation, ultracentrifugation, and enzymatic characterisation
[33]. Such method was invaluable to understand localisation [34],
function [35], and substrate speciﬁcity [36] of the mammalian sEH
enzymes. Nonetheless, yields and purity were not suﬃcient to carry out
structural or accurate biophysical investigations. It is only with the
advent of sEH recombinant expression in S. frugiperda [37] that the ﬁrst
structure of murine sEH became available [1]. Since then, almost 100
structures have been deposited in the RCSB PDB, of both murine and
human recombinant sEH, puriﬁed from insect cells. These structures
showed many diverse compounds interacting with the enzyme, pro-
viding a precious tool for the characterisation and discovery of hsEH
inhibitors. However, baculovirus protein expression is time-consuming
and sometime technically challenging, welcoming the development of
simpler and more eﬃcient protocols of recombinant expression of the
enzyme. Nishi et al. [23] reported a protocol of expression and pur-
iﬁcation of the full length hsEH from E. coli BL21(DE3) cells, obtaining
around 2mg/L of pure and active protein: nonetheless, in our hands,
this method yielded even lower amounts of pure hsEH. We have
therefore developed alternative expression and puriﬁcation methods of
both full-length protein and its functional C-terminal domain, which is
necessary and suﬃcient for the EETs epoxy-hydrolytic activity of the
enzyme. hsEH FL was obtained from mammalian HEK293-F cells, ob-
taining around 2mg of protein from only 250mL of culture. The
Fig. 3. Puriﬁcation of hsEH CTD. A. IMAC elution proﬁle. The elution produced two peaks, distinguishable between fractions 5 and 75. B. SDS-PAGE analysis of
IMAC fractions. The second elution peak contained hsEH CTD. C. SDS-PAGE analysis following BTS puriﬁcation. The high aﬃnity and speciﬁcity of BTS increased
signiﬁcantly the purity of the hsEH CTD sample. D. SEC elution proﬁle. The hsEH CTD was eluted in a single peak between fractions 26 and 45. E. SDS-PAGE analysis
of SEC fractions. The elution peak showed high purity levels and no signs of degradation.
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Fig. 4. ESI-MS analyses of intact hsEH CTD and FL.
A. m/z detection of intact hsEH CTD. The m/z
spectrum showed a Gaussian-type distribution of
multiply charged ions ranging from m/z 1275.2 to
2475.7. B. Deconvolution of intact hsEH CTD m/z
spectrum. The mass of the recombinant hsEH CTD
was 39497.9 Da, virtually identical to the one com-
puted with ProtParam. C. m/z detection of intact
hsEH FL. The m/z spectrum showed a Gaussian-type
distribution of multiply charged ions ranging from
m/z 1196.3 to 2289.7. D. Deconvolution of intact
hsEH FL m/z spectrum. The deconvoluted mass of
the recombinant hsEH FL was 67582.1 Da, corre-
sponding to the molecular weight of the protein
upon N-terminal methionine excision.
Fig. 5. Western blotting analysis of hsEH CTD and FL. A. and C. Detection with anti-His-tag antibody for CTD and FL respectively. B. and D. Detection with anti-hsEH
antibody for CTD and FL respectively. Signal detection of hsEH CTD and FL revealed only one band with both the antibodies employed.
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optimised expression and puriﬁcation of hsEH CTD using bacterial ex-
pression, the fastest and cheapest method of protein production avail-
able, yielded approximately 6mg of pure protein per L of culture.
Moreover, we herein demonstrated that the FL and CTD exhibited vir-
tually identical turnover frequencies, suggesting that the CTD in isola-
tion can be utilised in future studies of hsEH epoxy hydrolytic enzy-
matic activity and inhibition.
In conclusion, we have provided new tools to prepare active hsEH
full-length or CTD, which will assist future drug discovery studies and
investigations of its biological function and mechanisms.
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